Oruka Therapeutics (NASDAQ:ORKA) Research Coverage Started at Guggenheim

Guggenheim started coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research note released on Monday morning, MarketBeat reports. The firm issued a buy rating and a $60.00 price objective on the stock.

Several other research firms have also recently commented on ORKA. Wedbush reaffirmed an “outperform” rating and issued a $40.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, August 12th. Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 18th. HC Wainwright reduced their price target on Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday. BTIG Research reissued a “buy” rating and set a $56.00 price target on shares of Oruka Therapeutics in a research note on Monday, September 29th. Finally, Barclays began coverage on Oruka Therapeutics in a research note on Monday, October 13th. They set an “overweight” rating and a $48.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $44.00.

Oruka Therapeutics Price Performance

ORKA stock opened at $27.61 on Monday. The company’s 50 day simple moving average is $19.62 and its 200-day simple moving average is $14.73. The firm has a market capitalization of $1.15 billion, a PE ratio of -9.83 and a beta of -0.29. Oruka Therapeutics has a 12 month low of $5.49 and a 12 month high of $30.40.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.02. As a group, sell-side analysts anticipate that Oruka Therapeutics will post -3.41 earnings per share for the current year.

Hedge Funds Weigh In On Oruka Therapeutics

Hedge funds have recently made changes to their positions in the stock. ADAR1 Capital Management LLC acquired a new position in shares of Oruka Therapeutics in the 1st quarter valued at $1,362,000. Affinity Asset Advisors LLC lifted its holdings in shares of Oruka Therapeutics by 47.9% during the 1st quarter. Affinity Asset Advisors LLC now owns 545,362 shares of the company’s stock valued at $5,595,000 after acquiring an additional 176,664 shares in the last quarter. Braidwell LP lifted its holdings in shares of Oruka Therapeutics by 37.0% during the 1st quarter. Braidwell LP now owns 1,572,426 shares of the company’s stock valued at $16,133,000 after acquiring an additional 424,750 shares in the last quarter. OMERS ADMINISTRATION Corp lifted its holdings in shares of Oruka Therapeutics by 126.8% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 44,900 shares of the company’s stock valued at $461,000 after acquiring an additional 25,100 shares in the last quarter. Finally, Candriam S.C.A. acquired a new position in shares of Oruka Therapeutics during the 1st quarter valued at $1,197,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.